SYROS PHARMACEUTICALS INC's ticker is SYRS and the CUSIP is 87184Q107. A total of 73 filers reported holding SYROS PHARMACEUTICALS INC in Q4 2019. The put-call ratio across all filers is - and the average weighting 0.5%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2021 | $57,684,000 | -41.2% | 7,711,724 | -14.7% | 0.12% | -55.9% |
Q4 2020 | $98,098,000 | -1.0% | 9,041,321 | -19.4% | 0.26% | -55.6% |
Q3 2020 | $99,119,000 | +9.2% | 11,212,506 | +31.7% | 0.59% | -39.8% |
Q2 2020 | $90,750,000 | +159.4% | 8,513,133 | +44.3% | 0.98% | +11.9% |
Q1 2020 | $34,983,000 | -0.3% | 5,899,398 | +16.2% | 0.87% | -1.5% |
Q4 2019 | $35,088,000 | -11.8% | 5,077,807 | +32.4% | 0.88% | +1.8% |
Q3 2019 | $39,804,000 | +13.4% | 3,834,728 | +1.1% | 0.87% | -1.8% |
Q2 2019 | $35,112,000 | +28.4% | 3,791,756 | +26.7% | 0.88% | +13.3% |
Q1 2019 | $27,353,000 | +99.6% | 2,992,700 | +21.6% | 0.78% | +40.2% |
Q4 2018 | $13,706,000 | -48.2% | 2,460,621 | +10.7% | 0.56% | -30.4% |
Q3 2018 | $26,462,000 | +44.0% | 2,221,870 | +23.5% | 0.80% | +18.9% |
Q2 2018 | $18,373,000 | -5.9% | 1,799,553 | +19.6% | 0.67% | -30.6% |
Q1 2018 | $19,533,000 | +140.5% | 1,504,890 | +80.3% | 0.97% | +49.9% |
Q4 2017 | $8,122,000 | +2749.8% | 834,757 | +4614.8% | 0.65% | +1076.4% |
Q2 2017 | $285,000 | +117.6% | 17,705 | +114.7% | 0.06% | +44.7% |
Q1 2017 | $131,000 | +211.9% | 8,245 | +137.5% | 0.04% | +153.3% |
Q4 2016 | $42,000 | – | 3,471 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Ally Bridge Group (NY) LLC | 3,539,895 | $11,540,000 | 4.03% |
Bain Capital Life Sciences Investors, LLC | 6,264,420 | $20,422,000 | 1.62% |
Samsara BioCapital, LLC | 2,189,199 | $6,243,000 | 1.21% |
Omega Fund Management, LLC | 2,512,705 | $8,191,000 | 1.16% |
Altium Capital Management LP | 1,160,000 | $3,782,000 | 1.04% |
Sio Capital Management, LLC | 900,677 | $2,936,000 | 0.88% |
Artal Group S.A. | 3,000,000 | $9,780,000 | 0.26% |
Flagship Pioneering Inc. | 2,938,494 | $9,579,000 | 0.15% |
GSA CAPITAL PARTNERS LLP | 242,132 | $789,000 | 0.10% |
Orbimed Advisors | 1,837,500 | $5,990,000 | 0.08% |